WEARABLE-TECHNOLOGY-SHOW
23.1.2017 14:20:53 CET | Business Wire | Press release
The Wearable Technology Show returns to London in March for its fourth outing with a strengthened focus on digital health, 6,000 attendees in its sights, global leaders and influencers on its 200-speaker strong conference programme and over 100 exhibitors showcasing the latest innovations in smart technology.
The fourth Wearable Technology Show takes place 7-8 March at ExCeL and is co-located with the AR, VR & MXR Show , IOT Connect and the brand new Digital Health Technology Show , making it Europe’s biggest event for wearables, AR & VR, IOT and connected technology.
Speakers already confirmed for 2017 include the following keynotes:
- Vincent Nida, Global Brand President, L’Oreal
- Greg Ivanov, Business Head, Google Daydream
- Rachel Murphy, Digital Delivery Director, NHS Digital
- Steve Moore, Director of Connected Home, Dixons Carphone
100 exhibitors from more than 20 countries will be on the show floor unveiling brand new products and prototypes, many of which will never have been seen before in Europe. For example:
-
MyndPlay
Fronted by former Apprentice candidate, Tre Azam, MyndPlay is behind the revolutionary VR-ready MyndBand EEG Brainwave headset and the MyndPlayer interactive mind controlled video platform which allows users to control, influence and interact with videogames, apps and movies using their mind and emotions.
-
Navdy
The Navdy Head-Up Display integrates AR with driving, to give you access to distraction-free information on a transparent screen as you drive -
Stretchsense
The leading supplier of smart stretch sensors, Stretchsense’s lightweight, flexible fabric stretch sensors and low-powered circuits can be integrated into garments to feed back precise, real-time motion data to the user’s portable device.
-
Glass Up
GlassUp are the brains behind the UNO smart eyewear, which use AR to give the wearer access to incoming e-mails, texts and social media updates.
And in the Digital Health Technology Show:
-
Touch Surgery
Straight from rave reviews at CES, Touch Surgery is the leading mobile surgical simulation platform with amazing new surgical training capabilities, allowing people to perform next to ‘real-life’ surgical procedures.
-
E-Sense
Also previewed at CES, E-Sense’s Helios Smart Ring has three smart coaches to monitor and coach our Vitamin D, sunlight and daylight intake and exposure
-
Proximie
A revolutionary application transforming the way surgeons work and teach, using an interactive AR platform that gives surgical support seamlessly from anywhere in the world, resulting in better patient care, reduced costs and a highly engaging training experience.
-
Activbody
UK launch of Activ5 wellbeing tool, a wireless-enabled, handheld isometric-based strength training device that, along with the Activ5 Companion App, coaches users through five-minute full body workouts and measures data such as strength, precision and other personal metrics.
“The Wearable Technology Show continues to grow from strength to strength, breaking new boundaries in terms of our global audience, reach and content each year,” commented COO John Weir.
“The launch of the Digital Health Technology Show for 2017 is particularly exciting for visitors: digital health is one of the most innovative, ground-breaking and, literally, life-changing areas of smart technology.”
Registration is open now at http://www.wearabletechnologyshow.net/home
Notes to editors:
About Wearable Technology Show
The Wearable Technology Show is Europe’s biggest event for wearables, AR and VR, IoT and Connected Technology. Over 6,000 are expected to attend this year’s event – the fourth - to hear from some of the top names in wearables, digital health, AR/VR, and IOT. The Wearable Technology Show is co-located with the AR, VR & MXR Show, Europe's largest independent event for AR, VR and Mixed Reality, as well as IOT Connect – dedicated to the connected enterprise.
2017 will also see the launch of the Digital Health Technology Show, where delegates can see the future of healthcare and learn about the latest disruptive technology transforming the medical sector.
With over 200 speakers, the conference programme will deliver the most comprehensive, entertaining and inspiring programme of any technology show around. The Wearable Technology Show boasts ten conference tracks:
- Wearable Disrupt
- Performance Sports
- AR, VR & MXR
- Digital Health Keynote
- Smart Textiles & Sensors
- Smart Home & Connected Living
- IoT Connect
- IoT & Apps Developers
- Innovation Showcase
- Digital Health Innovation
For more information: www.wearabletechnologyshow.net /@wearabletecshow #WTS2017
Press can register for the show at http://www.wearabletechnologyshow.net/press-registration
View source version on businesswire.com: http://www.businesswire.com/news/home/20170123005545/en/
Contact:
BIGTOP PR
Charlie Le Rougetel
07736 330676
charlie@bigtop-pr.co.uk
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom